Physician profile
Manuel A Martinez
NPI 1043262769
$9,388.47
in general payments reported to CMS, 2019-2025
26 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $102 · 2021: $122 · 2022: $665 · 2023: $6,924 · 2024: $448 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $1,197 · Travel and Lodging: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $1,197.13 |
| Travel and Lodging | $421.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,559.07 | 2022-2023 | Da Vinci Surgical System, Ion |
| Ethicon INC. | $929.74 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.54 | 2020-2025 | Stiolto Respimat, Ofev, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $222.22 | 2021-2023 | Glassia |
| Genzyme Corporation | $182.49 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $180.62 | 2019-2025 | Fasenra, Tezspire |
| Mallinckrodt Hospital Products INC. | $156.13 | 2022-2023 | Acthar |
| Abbvie INC. | $126.16 | 2024-2025 | |
| Glaxosmithkline, LLC. | $89.73 | 2020-2024 | Nucala |
| Genentech USA, INC. | $63.44 | 2019-2020 | |
| Philips North America LLC | $62.40 | 2019-2024 | (Ak6) Vest Therapy |
| Electromed, INC. | $55.90 | 2019-2025 | Smartvest |
| United Therapeutics Corporation | $52.10 | 2024-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $48.36 | 2023-2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $46.89 | 2022-2024 | Dupixent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $45.87 | 2025 | Tavneos, Tezspire |
| Pharming Healthcare, INC. | $45.58 | 2023-2024 | Ruconest |
| Inogen, INC. | $33.73 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Mylan Specialty L.P. | $28.63 | 2022-2024 | Yupelri |
| Abiomed | $27.83 | 2025 | |
| Bard Peripheral Vascular, INC. | $25.37 | 2024 | |
| Baxter Healthcare | $24.85 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Merck Sharp & Dohme LLC | $22.52 | 2024 | Keytruda |
| Janssen Pharmaceuticals, INC | $18.03 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $16.74 | 2024 | Opsumit, Uptravi |
| Verona Pharma, INC. | $16.53 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.